Inhibition of CIA by MBP-C5a vaccination.
Mean clinical score of arthritis severity from two representative experiments; A. (BALB/c x B10.Q) F1 male mice (8 weeks old) received vaccination subcutaneously of 100 µg MBP-C5a or PBS emulsified in CFA on day −21 and were re-vaccinated on days −3 and +28 with 50 µg of MBP-C5a or PBS emulsified in IFA as indicated by arrows. B. Similar protocol as above including MBP group. In both the experiments, mice were immunized with 100 µg of rat CII in CFA on day 0. Serum samples were collected on days 0 and 35. All the animals were included for calculations and the data represent mean ± SEM. Significance of differences in severity of arthritis between MBP-C5a and PBS groups was analyzed by Mann–Whitney U ranking test. *, p<0.05; **, p<0.005 and ***, p<0.001. 100% and 44% of mice developed arthritis in PBS or MBP-C5a vaccinated groups in the first experiment. During the second experiment, 13%, 60% and 69% of the mice developed arthritis in MBP-C5a, MBP or PBS vaccinated groups. C) Anti-CII antibody levels in the above two experiments. No significant difference in CII-specific antibody levels was observed between groups. n, denotes number of mice used in each group.